Below are some of the honors recently given to leaders at NYU Langone:
Joaquin González, PhD, Awarded Pew Fellowship for Sleep and Memory Research at NYU Langone
Joaquin González, PhD, a postdoctoral fellow at NYU Grossman School of Medicine, has been named a 2026 Pew Latin American Fellow in the Biomedical Sciences by the Pew Charitable Trusts. As part of this highly competitive program, Dr. González will receive two years of funding to support his work in the laboratory of György Buzsáki, MD, PhD, a leader in systems and computational neuroscience in NYU Grossman School of Medicine’s neuroscience and neurology departments.
Dr. González studies how the brain turns new experiences into lasting memories during sleep. When we see something, different parts of the brain work together to notice what and where it is. This information is first stored in a brain area called the hippocampus, then later moved to another part of the brain for long-term storage. Dr. González uses advanced tools to watch and control brain activity in sleeping animals, turning certain brain circuits on or off to observe how this changes what the animals remember later on. His work may help us better understand how memories form and how we might improve learning.
Shohei Koide, PhD, Awarded a 2026 Stephenson Global Scholar Grant
Shohei Koide, PhD, has been selected by the Stephenson Global Pancreatic Cancer Research Institute for an elite global award to tackle pancreatic cancer.
Dr. Koide, the inaugural director of cancer biologics at Perlmutter Cancer Center, is one of eight investigators worldwide chosen to receive a grant for 2026. The highly selective program is awarding $6.7 million to advance bold ideas in pancreatic cancer research. Under this award, Dr. Koide’s charge will be to develop antibodies targeting LCN2, a protein that helps pancreatic tumors keep out cancer-fighting immune cells. An elected fellow of the National Academy of Inventors, Dr. Koide is known for the invention of the widely adopted monobody platform. Formed from a simple protein framework, a parental monobody can be quickly turned into trillions of slightly different versions, which are then screened to see which ones interrupt signals sent via abnormal proteins during cancerous growth.
